Elafibranor (Iqirvo) was well tolerated and led to sustained improvements in liver enzyme levels and itch severity through 28 weeks in patients with primary sclerosing cholangitis (PSC), according to ...

Interim data from the IQIRVO ® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in ...

According to DataM Intelligence, the NASH/MASH Treatment Market Size was valued at USD 7.87 billion in 2024 and is projected to reach USD 31.76 billion by 2033, expanding at a robust 17.7% CAGR from ...

According to DataM Intelligence, the NASH/MASH Treatment Market Size was valued at USD 7.87 billion in 2024 and is projected to ...

The peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor family. Three PPAR isotypes—α, β/δ, and γ—have been identified. 1 Although all PPARs are quite widely expressed, ...

ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in improvement of fatigue and pruritus symptoms, ...

From skincare irritants to hormone concerns, we explore the role of fragrance and relevance in beauty products.

Gilead’s Livdelzi demonstrates sustained efficacy in PBC, offering ALP reduction, itch relief and potential to slow disease progression: Foster City, California Monday, November ...

The expansion of the cholestatic pruritus market across the US will be driven by the introduction of innovative therapies, Linerixibat, Volixibat, and TH104, among others. Furthermore, the rising ...

Scientists have long searched for ways to help the body burn more energy without requiring intense exercise or drastic lifestyle changes. A surge of interest has centered on thermogenesis, the process ...